The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer
Open accessAbstract
The mechanistic contributions of cancer-associated fibroblasts (CAFs) in breast cancer progression remain to be fully understood. While altered glucose metabolism in CAFs could fuel cancer cells, how such metabolic reprogramming emerges and is sustained needs further investigation. Studying fibroblasts isolated from patients with benign breast tissues and breast cancer, in conjunction with multiple animal models, we demonstrate that CAFs exhibit a metabolic shift toward lactate and pyruvate production and fuel biosynthetic pathways of cancer cells. The depletion or suppression of the lactate production of CAFs alter the tumor metabolic profile and impede tumor growth. The glycolytic phenotype of the CAFs is in part sustained through epigenetic reprogramming of HIF-1α and glycolytic enzymes. Hypoxia induces epigenetic reprogramming of normal fibroblasts, resulting in a pro-glycolytic, CAF-like transcriptome. Our findings suggest that the glucose metabolism of CAFs evolves during tumor progression, and their breast cancer-promoting phenotype is partly mediated by oxygen-dependent epigenetic modifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Enhanced glycolysis supports the increased demand for biosynthetic products necessary for cancer cell growth and multiplication (Pavlova and Thompson, 2016; Vander Heiden and DeBerardinis, 2017).”
BackgroundThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Self-citationOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Self-citationUnderstanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
The biology and function of exosomes in cancer
Kalluri, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81135 · Cited by 1,849
Self-citationFibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 1×
“Breast CAFs are a diverse population of mesenchymal cells identified by various protein markers (Costa et al., 2018; Kalluri, 2016b; Sugimoto et al., 2006; Tchou et al., 2012).”
BackgroundEvidence that fibroblasts derive from epithelium during tissue fibrosis
Iwano, M., Plieth, D., Danoff, T. M., Xue, C., Okada, H., & Neilson, E. G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215518 · Cited by 1,590
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway
Stincone, A., Prigione, A., Cramer, T., Wamelink, M. M. C., Campbell, K., Cheung, E., Olin‐Sandoval, V., Grüning, N., Krüger, A., Tauqeer Alam, M., et al. (2015) · Biological Reviews · doi:10.1111/brv.12140 · Cited by 1,576
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
Cited by
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Self-citationCox, T. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 976
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572
Kugeratski, F. G., Hodge, K., Lilla, S., McAndrews, K. M., Zhou, X., Hwang, R. F., Zanivan, S., & Kalluri, R. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00693-y · Cited by 488
Self-citationMetabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming
Li, Z., Sun, C., & Qin, Z. (2021) · Theranostics · doi:10.7150/thno.62378 · Cited by 390
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
Grout, J. A., Sirven, P., Leader, A. M., Maskey, S., Hector, E., Puisieux, I., Steffan, F., Cheng, E., Tung, N., Maurin, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1714 · Cited by 366
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12291 · Cited by 286
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12392 · Cited by 280
Inflammation: the incubator of the tumor microenvironment
Denk, D., & Greten, F. R. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.07.002 · Cited by 273
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Glycolysis: A multifaceted metabolic pathway and signaling hub
Kierans, S. J., & Taylor, C. T. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107906 · Cited by 198
The crosstalk between HIFs and mitochondrial dysfunctions in cancer development
Bao, X., Zhang, J., Huang, G., Yan, J., Xu, C., Dou, Z., Sun, C., & Zhang, H. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03505-1 · Cited by 152
Kitamura, F., Semba, T., Yasuda-Yoshihara, N., Yamada, K., Nishimura, A., Yamasaki, J., Nagano, O., Yasuda, T., Yonemura, A., Tong, Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163022 · Cited by 121
“For instance, lactate derived from 354 CAFs with enhanced glycolytic activity fueled breast cancer cell growth(47), and 355 CAF-secreted lactate induced lipid metabolic reprogramming that enhanced the 356 invasive capacity of prostate cancer(48).”
BackgroundDeterminants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
“Thus, it appears that fibroblasts consume pyruvate from the medium, an intriguing finding given that fibroblasts serve as a source of pyruvate in breast cancer.(57) We then investigated the list of secreted factors expressed by Kras-expressing epithelial cells in the”
BackgroundOncofetal reprogramming in tumour development and progression
Sharma, A., Blériot, C., Currenti, J., & Ginhoux, F. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00497-8 · Cited by 94
Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Metadata
- Authors
- Becker, L. M., O’Connell, J. T., Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H., McGow, A. K., Asara, J. M., Lovisa, S., McAndrews, K. M., Zielinski, R., Lorenzi, P. L., Zeisberg, M., Raza, S., LeBleu, V. S., & Kalluri, R.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 31
- Issue
- 9
- Pages
- 107701
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3029079472
- Cited by
- 291
- References
- 68
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.